1 November 2023 in Infection and Drug Resistance
The growing global apprehension towards multi-drug resistant (MDR) bacteria necessitates the development of innovative strategies to combat these infections. Berberine (BER), an isoquinoline quaternary alkaloid derived from various medicinal plants, has surfaced as a promising antibiotic adjuvant due to its ability to enhance the effectiveness of conventional antibiotics against drug-resistant bacterial strains. Here, we overview the augmenting properties and mechanisms of BER as an adjunctive antibiotic against MDR bacteria. BER has been observed to exhibit synergistic effects when co-administered with a range of antibiotics, including β-lactams, quinolones, aminoglycosides, tetracyclines, macrolides, lincosamides and fusidic acid. The adjunctive properties of BER led to an increase in antimicrobial effectiveness for these antibiotics against the corresponding bacteria, a decrease in minimal inhibitory concentrations, and even the reversal from resistance to susceptibility sometimes. The potential mechanisms responsible for these effects included the inhibition of antibiotic efflux, the disruption of biofilm formation, the modulation of host immune responses, and the restoration of gut microbiota homeostasis. In brief, BER demonstrated significant potential as an antibiotic adjuvant against MDR bacteria and is a promising candidate for combination therapy. Further research is necessary to fully elucidate its mechanism of action and address the challenges associated with its clinical application.
18 March 2022 in Genomics, Proteomics & Bioinformatics
The rapid spread of carbapenemase-producing Klebsiella pneumoniae (cpKP) poses serious threats to public health; however, the underlying genetic basis for its dissemination is still unknown. We conducted a comprehensive genomic epidemiology analysis on 420 cpKP isolates collected from 70 hospitals in 24 provinces/autonomous regions/municipalities of China during 2009–2017 by short-/long-read sequencing. The results showed that most cpKP isolates were categorized into clonal group 258 (CG258), in which ST11 was the dominant clone. Phylogenetic analysis revealed three major clades including the top one of Clade 3 for CG258 cpKP isolates. Additionally, carbapenemase gene analysis indicated that blaKPC was dominant in the cpKP isolates, and most blaKPC genes were located in five major incompatibility (Inc) groups of blaKPC-harboring plasmids. Importantly, three advantageous combinations of host–blaKPC-carrying plasmid (Clade 3.1+3.2–IncFIIpHN7A8, Clade 3.1+3.2–IncFIIpHN7A8:IncR, and Clade 3.3–IncFIIpHN7A8:IncpA1763-KPC) were identified to confer cpKP isolates the advantages in both genotypes (strong correlation/coevolution) and phenotypes (resistance/growth/competition) to facilitate the nationwide spread of ST11/CG258 cpKP. Intriguingly, Bayesian skyline analysis illustrated that the three advantageous combinations might be directly associated with the strong population expansion during 2007–2008 and subsequent maintenance of the population of ST11/CG258 cpKP after 2008. We then examined drug resistance profiles of these cpKP isolates and proposed combination treatment regimens for CG258/non-CG258 cpKP infections. Thus, the findings of our systematical analysis shed light on the molecular epidemiology and genetic basis for the dissemination of ST11/CG258 cpKP in China, and much emphasis should be given to the close monitoring of advantageous cpKP–plasmid combinations.
3 March 2017 in Turkish Journal of Gastroenterology
Turkjgastroenterol, Turkgastro
26 November 2024 in The Journal of Infectious Diseases
Mycobacterium abscessus (MAB) is intrinsically resistant to many antibiotics, but the evolution of acquired drug resistance is poorly understood. We analyzed published genomes of 5,617 clinical MAB isolates from 20 countries and searched for signals of ongoing evolution in 35 drug-resistance-associated genes. Of these, we found 14 genes were subject to positive selection and identified novel mutational sites under selection. Among these, the erm(41) V80I mutation arose exclusively in strains with erm(41) 28T and affected 50.5% (1750/3465) of subsp. abscessus isolates. The study provided evidence that MAB is evolving mutations in drug-resistance-associated genes, and further research is needed to understand the functional consequences of these mutations.
5 August 2025 in Genomics, Proteomics & Bioinformatics
Tuberculosis (TB) has returned as the leading cause of death caused by a single infectious agent in 2023. Human macrophages and their secreted exosomes play important roles in combating invading Mycobacterium tuberculosis (Mtb). However, a comprehensive understanding of the mechanisms underlying immune regulation in Mtb-infected macrophages, as well as the packaging mechanisms and anti-TB effects of Mtb-treated exosomes, is still lacking. Here, we conducted comprehensive analyses of the macrophages infected with avirulent and virulent Mtb strains (H37Ra and H37Rv) and their exosomes through omics and phenotypic approaches. The results showed that H37Ra stimulated strong immune responses and apoptosis in macrophages to eliminate invading Mtb, while H37Rv induced severe necrosis and immune escape for survival. Interestingly, our results suggest that macrophages kill Mtb in an interferon-gamma (IFN-γ)-independent but compensatory way, highlighting the central role of IFN signaling pathway in anti-TB response. Moreover, we observed selective transport of host and Mtb RNAs from macrophages to exosomes. Notably, H37Ra-treated exosomes displayed a higher anti-TB effect than H37Rv-treated exosomes due to some enriched pro-inflammatory and immune escape-related Mtb proteins in these two exosomes, respectively. In conclusion, our findings shed new light on the immune mechanisms of macrophages in response to Mtb infection, offering a new TB treatment strategy and promising vaccine candidates.
29 November 2024 in Journal of Global Antimicrobial Resistance
Certain rifampicin-resistant Mycobacterium tuberculosis (MTB) strains are susceptible to rifabutin (RFB) and may be amenable to RFB treatment. We performed a meta-analysis of available cross-sectional studies to determine the rifampicin (RIF) resistance mutations associated with RFB susceptibility. We identified studies through PubMed, Web of Science, Embase, and the Cochrane Library up to September 30, 2024. Studies that investigated RpoB mutations and reported phenotypic drug susceptibility to RIF and RFB met our criteria. The relationship between RIF-resistance mutations to RFB-susceptibility was evaluated using odds ratios (OR). Twenty-seven studies comprised 9222 clinical RIF-resistant MTB strains from 25 countries met the inclusion criteria. Of these strains, 14.93% (1377/9222) were susceptible to RFB. We found that 14 RIF-resistance mutations were associated with susceptibility to RFB. Among these, nine had high confidence (OR>10) in predicting RFB susceptibility: RpoB D435V, H445L, D435Y, D435F, S441L, L430P, H445G, S441Q, L430R. Among the strains carrying these mutations, 59.04% (702/1189) were susceptible to RFB. The ratio increased to 83.45% in studies following CLSI guidelines. The minimum inhibition concentrations (MICs) of these mutations revealed that they had low MIC to RFB and exhibited a lack of correlation between MICs for RIF and RFB. L452P, I491F, H445C, H445N, and D435G exhibited moderate confidence (5<OR≤10) in predicting susceptibility to RFB. S450L and S450W were associated with RFB-resistance (OR<1). These results provide a theoretical basis for the molecular detection of RFB-susceptible tuberculosis and alternative treatment with RFB in patients with multidrug-resistant/rifampicin-resistant tuberculosis.